1259279-60-1Relevant articles and documents
PYRROLO[2,3-B]PYRIDIN DERIVATIVES AS INHIBITORS OF INFLUENZA VIRUS REPLICATION
-
, (2020/02/16)
Provided herein are compounds of Formula A, B or C that can inhibit the replication of influenza viruses, reduce the amount of influenza viruses, and/or treat influenza.
Inhibitors of influenza viruses replication
-
Page/Page column 368, (2016/06/14)
Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.
Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2
Clark, Michael P.,Ledeboer, Mark W.,Davies, Ioana,Byrn, Randal A.,Jones, Steven M.,Perola, Emanuele,Tsai, Alice,Jacobs, Marc,Nti-Addae, Kwame,Bandarage, Upul K.,Boyd, Michael J.,Bethiel, Randy S.,Court, John J.,Deng, Hongbo,Duffy, John P.,Dorsch, Warren A.,Farmer, Luc J.,Gao, Huai,Gu, Wenxin,Jackson, Katrina,Jacobs, Dylan H.,Kennedy, Joseph M.,Ledford, Brian,Liang, Jianglin,Maltais, Fran?ois,Murcko, Mark,Wang, Tiansheng,Wannamaker, M. Woods,Bennett, Hamilton B.,Leeman, Joshua R.,McNeil, Colleen,Taylor, William P.,Memmott, Christine,Jiang, Min,Rijnbrand, Rene,Bral, Christopher,Germann, Ursula,Nezami, Azin,Zhang, Yuegang,Salituro, Francesco G.,Bennani, Youssef L.,Charifson, Paul S.
, p. 6668 - 6678 (2014/10/15)
In our effort to develop agents for the treatment of influenza, a phenotypic screening approach utilizing a cell protection assay identified a series of azaindole based inhibitors of the cap-snatching function of the PB2 subunit of the influenza A viral polymerase complex. Using a bDNA viral replication assay (Wagaman, P. C., Leong, M. A., and Simmen, K. A. Development of a novel influenza A antiviral assay. J. Virol. Methods 2002, 105, 105-114) in cells as a direct measure of antiviral activity, we discovered a set of cyclohexyl carboxylic acid analogues, highlighted by VX-787 (2). Compound 2 shows strong potency versus multiple influenza A strains, including pandemic 2009 H1N1 and avian H5N1 flu strains, and shows an efficacy profile in a mouse influenza model even when treatment was administered 48 h after infection. Compound 2 represents a first-in-class, orally bioavailable, novel compound that offers potential for the treatment of both pandemic and seasonal influenza and has a distinct advantage over the current standard of care treatments including potency, efficacy, and extended treatment window.
